Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
6.72 USD +3.07% Intraday chart for Cogent Biosciences, Inc. -1.61% +14.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures -2- DJ
Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating MT
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14 MT
Transcript : Cogent Biosciences, Inc. - Special Call
Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating MT
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis CI
Top Midday Gainers MT
Cogent Biosciences Launches $225 Million Private Placement; Shares Jump MT
Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target MT
Transcript : Cogent Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM
Cogent Biosciences Expects Certain Milestones for Bezuclastinib Trials in 2024 MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating MT
North American Morning Briefing : Traders Eye -2- DJ
Sector Update: Health Care Stocks Higher Late Afternoon MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Rise Monday Afternoon MT
Cogent Biosciences Says Phase 2 Trial of Bezuclastinib Showed 4 Related Serious Adverse Events; Shares Down MT
Cogent Biosciences, Inc. Announces Positive Initial Data from the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezculastinib in Patients with Advanced Systemic Metocytosis CI
Transcript : Cogent Biosciences, Inc. - Special Call
Cogent Biosciences Announces Positive Data from Part 1 of the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis CI
Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20 MT
Cogent Biosciences, Inc. Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis CI
JPMorgan Chase Starts Coverage on Cogent Biosciences with Overweight Rating, $18 Price Target MT
Chart Cogent Biosciences, Inc.
More charts
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
6.72 USD
Average target price
16.82 USD
Spread / Average Target
+150.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Cogent Biosciences, Inc. - Nasdaq
  4. News Cogent Biosciences, Inc.
  5. Wedbush Adjusts Price Target for Cogent Biosciences to $17 From $21, Maintains Outperform Rating